Skip to main content
OpenTrials
Completed

NCT Number: NCT05033483

Do Iron Supplements Impact the Gut Microbiome of Women of Reproductive Age?

In this randomised controlled trial the investigators will determine whether taking iron supplements compared to placebo for 21 days alters the bacteria (microbiome) in the large intestine of non-pregnant female participants.

Completed

Looking for future studies?

Notify Me

Key information

About this study

BACKGROUND: Many women take iron-containing supplements during pregnancy. Indeed, the World Health Organization recommends that all pregnant women in low-income countries take an iron supplement containing 60 mg/day of elemental iron to reduce iron deficiency and iron-deficiency anaemia. However, oral iron has poor bioavailability, less than 10% absorbed with the remainder passing into the large intestine unbound, potentially providing a competitive advantage to iron-dependent opportunistic pathogens in the large intestine.

In a large randomized control trial in children, iron supplementation was shown to promote the growth of pathogenic species (E. coli, S. aureus, and L. monocytogenes) and inhibited the growth of commensal species (Lactobacillus and Bifidobacterium). These pathogens are associated with enteric infections, while the commensals act on the host's immune system to prevent colonization and invasion by pathogens.

It is NOT known if iron supplementation during pregnancy impacts the maternal and infant microbiome and, by extension, how this affects the neonatal risk of infection and immune dysregulation. Vertical transmission of the maternal microbiome to the newborn is a major determinant of infant health. If maternal iron supplementation affects the infant's health, strategies would be required to mitigate this risk.

The investigators require preliminary data to show how oral iron supplementation alters the intestinal microbiome in women. The Investigators will recruit non-pregnant female participants as there is no risk of vertical transmission to an infant in non-pregnant women. The investigators will conduct the study in Australia because there is not a natural abundance of pathogens that could potentially cause harm to the women. Nevertheless, the investigators would expect a shift in the microbiome from non-iron to iron, requiring bacterial species to return to baseline after women stop taking the iron.

HYPOTHESIS: Daily iron supplementation versus placebo for 21 days will alter the stool microbiome composition compared to placebo in non-pregnant female participants of reproductive age.

METHODS: 80 female participants (18-45 y) will be randomized to receive capsules containing iron (65.7 mg of elemental iron as ferrous fumarate) or placebo to take daily for 21 days. Stool samples will be collected at baseline, 21 days, and 42 days (washout).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to give informed consent

Exclusion criteria

  • Pregnant or breastfeeding.
  • Planning on becoming pregnant
  • Diagnosed with iron deficiency and/or anaemia in the previous three months
  • Taken antibiotics in the past three months
  • Taken iron containing supplements in the past three months

Treatment and study plan

ferrous fumarate

Dietary Supplement

Gelatin capsule containing 200 mg ferrous fumarate and microcrystalline cellulose

Other names: Iron Fumarate, ferro-tab

Placebo

Dietary Supplement

Gelatin capsule containing microcrystalline cellulose

Other names: Control

Primary outcomes

  1. Weighted UniFrac dissimilarity score

    Time frame: 21 days

    Measure of microbiota beta-diversity

Secondary outcomes

  1. Bray-Curtis dissimilarity score

    Time frame: 21 days

    Measure of microbiota beta-diversity

  2. Shannon Wiener Diversity

    Time frame: 21 days

    Microbiota alpha-diversity score with adjustment for baseline levels

  3. Faith's phylogenetic diversity

    Time frame: 21 days

    Microbiota alpha-diversity score with adjustment for baseline levels

  4. Taxonomic richness

    Time frame: 21 days

    Microbiota alpha-diversity score with adjustment for baseline levels

  5. Relative abundance of core bacterial taxa

    Time frame: 21 days

    Relative abundance of taxa present in >40% of baseline samples, with adjustment for baseline levels

Other outcomes

  1. Weighted UniFrac dissimilarity score

    Time frame: 42 days (washout)

    Measure of microbiota beta-diversity

  2. Shannon-Wiener diversity

    Time frame: 42 days (washout)

    Microbiota alpha-diversity score with adjustment for baseline levels

  3. Bray-Curtis dissimilarity score

    Time frame: 42 days (washout)

    Measure of microbiota beta-diversity

  4. Faith's phylogenetic diversity

    Time frame: 42 days (washout)

    Microbiota alpha-diversity score with adjustment for baseline levels

  5. Taxonomic richness

    Time frame: 42 days (washout)

    Microbiota alpha-diversity score with adjustment for baseline levels

  6. Relative abundance of core bacterial taxa

    Time frame: 42 days (washout)

    Relative abundance of taxa present in >40% of baseline samples, with adjustment for baseline levels

Sponsors and collaborators

Lead sponsor

South Australian Health and Medical Research Institute

Other

Collaborators

  • Flinders University

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2022
First posted
Sep 2, 2021
Registry last updated
Apr 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.